Last updated on July 2019

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Brief description of study

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Clinical Study Identifier: NCT02869789

Find a site near you

Start Over

Essex Oncology Of North Jersey P.A.

Belleville, NJ United States
  Connect »

Saint Barnabas Medical Cancer Center

Livingston, NJ United States
  Connect »

Summit Medical Group

Florham Park, NJ United States
  Connect »